Crinetics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2008-01-01
- Employees
- 290
- Market Cap
- $4.3B
- Website
- http://www.crinetics.com
- Introduction
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.
Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in ...
Crinetics Pharmaceuticals announced positive Phase 2 results for atumelnant, showing significant reductions in CAH biomarkers and improvements in clinical signs. The drug was well-tolerated, supporting the initiation of a Phase 3 trial. Atumelnant, a novel ACTH receptor antagonist, demonstrated rapid, substantial reductions in androstenedione and 17-OHP levels.
Atumelnant Reduces Key CAH Biomarkers, Hits Primary Endpoints in Phase 2 TouCAHn Trial
Phase 2 TouCAHn trial results for atumelnant, an oral ACTH receptor antagonist, showed significant reductions in CAH biomarkers and improved symptoms. Administered once daily, it led to rapid decreases in androstenedione levels and normalized testosterone in females, with a tolerable safety profile. Crinetics plans Phase 3 trials for adults and Phase 2b/3 for children with CAH.
Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
Crinetics Pharmaceuticals announced positive Phase 2 results for atumelnant, showing significant reductions in CAH biomarkers and improvements in symptoms. The drug was well-tolerated, supporting a Phase 3 trial. Atumelnant, a novel ACTH receptor antagonist, demonstrated rapid, substantial biomarker reductions and symptom improvements in CAH patients.
Crinetics' CAH Drug Atumelnant Shows Remarkable 80% Efficacy in Phase 2 Trials
Crinetics announced positive Phase 2 trial results for atumelnant in treating congenital adrenal hyperplasia (CAH), showing significant biomarker reductions and clinical improvements. The drug was well-tolerated, supporting a Phase 3 trial initiation. Crinetics plans further studies in pediatric patients and additional drug candidates.
Crinetics Pharmaceuticals Announces Positive Phase 2 Results for Atumelnant
Crinetics Pharmaceuticals announced positive Phase 2 results for atumelnant, showing significant reductions in CAH biomarkers and improvements in symptoms. The drug was well-tolerated, supporting a Phase 3 trial initiation. A conference call to discuss results is scheduled.
Crinetics Announces Positive Topline Results From Phase 2
Crinetics Pharmaceuticals announced positive Phase 2 results for atumelnant, showing significant reductions in CAH biomarkers and improvements in symptoms. The drug was well-tolerated, supporting a Phase 3 trial. Atumelnant, an ACTH receptor antagonist, demonstrated rapid, substantial biomarker reductions, including up to 80% in androstenedione levels.
Crinetics announces FDA acceptance of NDA for paltusotine
Crinetics Pharmaceuticals' NDA for paltusotine, a once-daily oral treatment for acromegaly, was accepted by the FDA. If approved, it will be the first of its kind, offering an alternative to current peptide analog drugs. Crinetics is preparing for a potential commercial launch.
Promising Outlook for Crinetics Pharmaceuticals' Paltusotine in Phase 3 Trial Drives Buy Rating
Cory Jubinville, PhD from LifeSci Capital maintains a Buy rating on Crinetics Pharmaceuticals (CRNX) with a $82.00 price target, citing promising developments in paltusotine's Phase 3 trial for carcinoid syndrome (CS). Earlier Phase 2 results showed robust efficacy, supporting the Buy rating. Morgan Stanley also maintains a Buy rating with a $70.00 price target.
Global Cancer Gene Therapy Market Set for Significant Growth, Projected to Reach USD ...
The global cancer gene therapy market is projected to grow from USD 1,822.2 million in 2024 to USD 3,142.2 million by 2034, driven by increased R&D funding, rising cancer prevalence, and favorable government regulations. Oncolytic virotherapy, a key segment, generated USD 850.7 million in 2023. The market is shifting towards personalized, targeted therapies, reducing side effects and improving outcomes.
Crinetics Announces Positive Initial Findings at ENDO
Atumelnant (80 mg) showed significant efficacy in reducing androstenedione (A4) and 17-hydroxyprogesterone (17-OHP) levels in CAH patients, with 100% maintaining A4 below normal limits. It also normalized cortisol in ACTH-dependent Cushing’s syndrome patients. The drug was well-tolerated, with mild to moderate adverse events.
© Copyright 2025. All Rights Reserved by MedPath